Long-term effect of intra-arterial thrombolysis in stroke

Stroke

Volumn 37, Issue 12, 2006, Pages 3002-3007

  Nedeltchev, Krassen ^a   Fischer, Urs ^a   Arnold, Marcel ^a   Ballinari, Pietro ^a   Haefeli, Tobias ^a   Kappeler, Liliane ^a   Brekenfeld, Caspar ^a   Remonda, Luca ^a   Schroth, Gerhard ^a   Mattle, Heinrich P ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Intra arterial thrombolysis; Long term outcome; Stroke; Urokinase

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; UROKINASE;

ADULT; AGE; ALGORITHM; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DEMOGRAPHY; DIABETES MELLITUS; EMBOLISM; FEMALE; FIBRINOLYTIC THERAPY; GENDER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PREVALENCE; PRIORITY JOURNAL; RANKIN SCALE; SECONDARY PREVENTION; SMOKING; STATISTICAL ANALYSIS; STROKE; SWITZERLAND; TREATMENT OUTCOME;

AGED; CEREBROVASCULAR ACCIDENT; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRA-ARTERIAL; MALE; MIDDLE AGED; REGISTRIES; THROMBOLYTIC THERAPY; TIME FACTORS;

EID: 33845393130     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000249417.24085.80     Document Type: Article

References (31)

1. The National Institute of Neurological Disorders and Stroke rt-PA, Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1588.
2. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F, for the PROACT Investigators. Intra-arterial prourokinase for acute ischemic stroke: The PROACT II study: A randomized controlled trial. JAMA. 1999;282:2003-2011.
3. Hacke W, Bluhmki E, Steiner T, Tatlisumak T, Mahagne M-H, Sacchetti M-L, Meier D. Dichotomized efficacy end points and global end-point analysis applied to the ECASS intention-to-treat data set: post hoc analysis of ECASS I. Stroke. 1998;29:2073-2075.
4. Trouillas P, Nighoghossian N, Derex L, Adeleine P, Honnorat J, Neuschwander P, Riche G, Getenet J-C, Li W, Froment J-C, Turjman F, Malicier D, Fournier G, Gabry AL, Ledoux X, Berthezene Y, Ffrench P, Dechavanne M. Thrombolysis with intravenous rtPA in a series of 100 cases of acute carotid territory stroke: determination of etiological, topographic, and radiological outcome factors. Stroke. 1998;29:2529-2540.
5. Ernst R, Pancioli A, Tomsick T, Kissela B, Woo D, Kanter D, Jauch E, Carrozzella J, Spilker J, Broderick J. Combined intravenous and intra-arterial recombinant tissue plasminogen activator in acute ischemic stroke. Stroke. 2000;31:2552-2557.
6. Koennecke H-C, Nohr R, Leistner S, Marx P. Intravenous tPA for ischemic stroke team performance over time, safety, and efficacy in a single-center, 2-year experience. Stroke. 2001;32:1074-1078.
7. Arnold M, Schroth G, Nedeltchev K, Loher T, Remonda L, Stepper F, Sturzenegger M, Mattle HP. Intra-arterial thrombolysis in 100 patients with acute stroke due to middle cerebral artery occlusion. Stroke. 2002;33:1828-1833.
8. Rother J, Schellinger PD, Gass A, Siebler M, Villringer A, Fiebach JB, Fiehler J, Jansen O, Kucinski T, Schoder V, Szabo K, Junge-Hulsing GJ, Hennerici M, Zeumer H, Sartor K, Weiller C, Hacke W. Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke <6 hours. Stroke. 2002;33:2438-2445.
9. Labiche LA, Al-Senani F, Wojner AW, Grotta JC, Malkoff M, Alexandrov AV. Is the benefit of early recanalization sustained at 3 months?: a prospective cohort study. Stroke. 2003;34:695-698.
10. Schenkel J, Weimar C, Knoll T, Haberl RL, Busse O, Hamann GF, Koennecke H-C, Diener H-C. R1 - systemic thrombolysis in German stroke units. J Neurol. 2003;250:320-324.
11. Lindsberg PJ, Soinne L, Roine RO, Salonen O, Tatlisumak T, Kallela M, Happola O, Tiainen M, Haapaniemi E, Kuisma M, Kaste M. Community-based thrombolytic therapy of acute ischemic stroke in Helsinki. Stroke. 2003;34:1443-1449.
12. Arnold M, Nedeltchev K, Schroth G, Baumgartner RW, Remonda L, Loher TJ, Stepper F, Sturzenegger M, Schuknecht B, Mattle HP. Clinical and radiological predictors of recanalisation and outcome of 40 patients with acute basilar artery occlusion treated with intra-arterial thrombolysis. J Neurol Neurosurg Psychiatry. 2004;75:857-862.
13. Schmulling S, Grond M, Rudolf J, Heiss W-D. One-year follow-up in acute stroke patients treated with rtPA in clinical routine. Stroke. 2000;31:1552-1554.
14. Keris V, Rudnicka S, Vorona V, Enina G, Tilgale B, Fricbergs J. Combined intraarterial/intravenous thrombolysis for acute ischemic stroke. AJNR Am J Neuroradiol. 2001;22:352-358.
15. Kwiatkowski TG, Libman RB, Frankel M, Tilley BC, Morgenstern LB, Lu M, Broderick JP, Lewandowski CA, Marler JR, Levine SR, Brott T, The National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med. 1999;340:1781-1787.
16. Thomassen L, Waje-Andreassen U, Naess H, Elvik MK, Russell D. Long-term effect of intravenous thrombolytic therapy in acute stroke: Responder analysis versus uniform analysis of excellent outcome. Cerebrovasc Dis. 2005;20:470-474.
17. Aho K, Harmsen P, Hatano S, Marquardsen J, Smirnov VE, Strasser T. Cerebrovascular disease in the community: results of a WHO collaborative study. Bull World Health Organ. 1980;58:113-130.
18. Adams H Jr, Bendixen B, Kappelle L, Biller J, Love B, Gordon D, Marsh E 3rd. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST (Trial of Org 10172 in Acute Stroke Treatment). Stroke. 1993;24:35-41.
19. Brott T, Marler J, Olinger C, Adams H Jr, Tomsick T, Barsan W, Biller J, Eberle R, Hertzberg V, Walker M. Measurements of acute cerebral infarction: lesion size by computed tomography. Stroke. 1989;20:871-875.
20. European stroke initiative recommendations for stroke management - update 2003. Cerebrovasc Dis. 2003;16:311-337.
21. van Swieten J, Koudstaal P, Visser M, Schouten H, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604-607.
22. Hankey GJ. Long-term outcome after ischaemic stroke/ transient ischaemic attack. Cerebrovasc Dis. 2003;16(Suppl 1):14-19.
23. Arnold M, Nedeltchev K, Mattle HP, Loher TJ, Stepper F, Schroth G, Brekenfeld C, Sturzenegger M, Remonda L. Intra-arterial thrombolysis in 24 consecutive patients with internal carotid artery T occlusions. J Neurol Neurosurg Psychiatry. 2003;74:739-742.
24. Nedeltchev K, der Maur TA, Georgiadis D, Arnold M, Caso V, Mattle HP, Schroth G, Remonda L, Sturzenegger M, Fischer U, Baumgartner RW. Ischaemic stroke in young adults: predictors of outcome and recurrence. J Neurol Neurosurg Psychiatry. 2005;76:191-195.
25. Mattle HP, Schroth G, Arnold M, Remonda L, Nedeltchev K, Fischer U, Brelenfeld C. Endovascular treatment of acute ischemic stroke. Neurology. 2006;66(Suppl 2):A357.
26. Kent DM, Price LL, Ringleb P, Hill MD, Selker HP. Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke: a pooled analysis of randomized clinical trials. Stroke. 2005;36:62-65.
27. Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke. 2000;31:1062-1068.
28. Di Carlo A, Lamassa M, Baldereschi M, Pracucci G, Consoli D, Wolfe CDA, Giroud M, Rudd A, Burger I, Ghetti A. Risk factors and outcome of subtypes of ischemic stroke. Data from a multicenter multinational hospital-based registry. The European Community Stroke Project. J Neurol Sci. 2006;244:143-150.
29. The SITS collaborators. Thrombolysis for acute ischemic stroke: Main outcome results for 2003-2005 of SITS-MOST in Europe (Safe Implementation of Thrombolysis in Stroke Monitoring Study. Data presented at the 15th European Stroke Conference in Brussels, Belgium, on May 17, 2006.
30. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S, for The DIAS Study Group. The desmoteplase in acute ischemic stroke trial (DIAS): A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005;36:66-73.
31. Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, Sachara C, Soehngen M, Warach S, Hacke W, for the DEDAS Investigators. Dose escalation of desmoteplase for acute ischemic stroke (DEDAS): Evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke. 2006;37:1227-1231.